ciprofloxacin has been researched along with Otitis Externa in 85 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Otitis Externa: Inflammation of the OUTER EAR including the external EAR CANAL, cartilages of the auricle (EAR CARTILAGE), and the TYMPANIC MEMBRANE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to evaluate the clinical efficacy of ciprofloxacin plus fluocinolone acetonide (antibiotic plus corticosteroid) ear drops compared to ciprofloxacin (antibiotic) ear drops in diffuse otitis externa." | 9.19 | Ciprofloxacin plus fluocinolone acetonide versus ciprofloxacin alone in the treatment of diffuse otitis externa. ( Fuste, J; Gómez, M; Lorente, J; Risco, J; Rivas, MP; Sabater, F, 2014) |
| "To compare treatment failure rates for the two major acute otitis externa (AOE) pathogens, Pseudomonas aeruginosa and Staphylococcus aureus, by topical therapy with ciprofloxacin 0." | 7.75 | Differences in bacteriologic treatment failures in acute otitis externa between ciprofloxacin/dexamethasone and neomycin/polymyxin B/hydrocortisone: results of a combined analysis. ( Dohar, JE; McLean, C; Roland, P; Stroman, DW; Wall, GM, 2009) |
| "For fifteen years oral ciprofloxacin has been the standard treatment for malignant otitis externa, a sometimes fatal osteomyelitis of the skull base usually caused by Pseudomonas aeruginosa." | 7.74 | Resistance of Pseudomonas to ciprofloxacin: implications for the treatment of malignant otitis externa. ( Bernstein, JM; Holland, NJ; Maw, AR; Porter, GC, 2007) |
| "In our series, resistance to ciprofloxacin in patients with malignant otitis externa is increasing over time." | 7.71 | Evolving resistant pseudomonas to ciprofloxacin in malignant otitis externa. ( Berenholz, L; Harell, M; Katzenell, U, 2002) |
| " Fifteen adverse events related to study medications were registered, all of which were mild or moderate." | 7.11 | Efficacy and Safety of Ciprofloxacin Plus Fluocinolone Acetonide Among Patients With Acute Otitis Externa: A Randomized Clinical Trial. ( Aazami, H; Acosta, AM; Ansley, JF; Chu, L; De Valle, O; Dennis, P; Ehmer, D; Hedrick, JA, 2022) |
| "Foam-based ciprofloxacin is a safe and an effective new treatment for AOE." | 6.75 | Comparison of safety and efficacy of foam-based versus solution-based ciprofloxacin for acute otitis externa. ( Eilat, E; Goldfarb, A; Marom, T; Rakover, Y; Roth, Y; Shlizerman, L; Yelin, R, 2010) |
| " Repeated measures models were applied to log-transformed data to assess dosing trends and Pearson correlations were calculated to assess concentration associations." | 6.74 | Plasma and ear tissue concentrations of enrofloxacin and its metabolite ciprofloxacin in dogs with chronic end-stage otitis externa after intravenous administration of enrofloxacin. ( Cole, LK; Hillier, A; Kwochka, KW; Lehman, AM; Papich, MG; Smeak, DD, 2009) |
| " Most adverse events were mild and unrelated to study medication in both treatment groups." | 6.73 | Comparison of efficacy and safety of ciprofloxacin otic solution 0.2% versus polymyxin B-neomycin-hydrocortisone in the treatment of acute diffuse otitis externa*. ( Drehobl, M; Goldstein, G; Guerrero, JL; Lacarte, PR; Luber, S; Mata, FS, 2008) |
| "Signs and symptoms of AOE, including ear inflammation, tenderness, edema and discharge (assessed on Days 3, 8 [End-of-Therapy] and 18 [Test-of-Cure]); microbiologic eradication (presumed or documented); and frequency of adverse events." | 6.71 | Efficacy and safety of topical ciprofloxacin/dexamethasone versus neomycin/polymyxin B/hydrocortisone for otitis externa. ( Conroy, PJ; Dupre, SJ; Garadi, R; Henry, DC; Hogg, LG; Pien, FD; Potts, SL; Roland, PS; Schultz, CC; Stroman, DW; Wall, GM, 2004) |
| "Ciprofloxacin thus appears to be a useful and effective agent in the local therapy of otitis externa." | 6.67 | Otitis externa: clinical comparison of local ciprofloxacin versus local oxytetracycline, polymyxin B, hydrocortisone combination treatment. ( Arnes, E; Dibb, WL, 1993) |
| " Due to the different dosing regimens, patients were not blinded, but they also were not directly informed of their treatment assignments." | 6.44 | Pooled analysis of two clinical trials comparing the clinical outcomes of topical ciprofloxacin/dexamethasone otic suspension and polymyxin B/neomycin/hydrocortisone otic suspension for the treatment of acute otitis externa in adults and children. ( Rahman, A; Rizwan, S; Wall, GM; Waycaster, C, 2007) |
| "We aimed to evaluate the clinical efficacy of ciprofloxacin plus fluocinolone acetonide (antibiotic plus corticosteroid) ear drops compared to ciprofloxacin (antibiotic) ear drops in diffuse otitis externa." | 5.19 | Ciprofloxacin plus fluocinolone acetonide versus ciprofloxacin alone in the treatment of diffuse otitis externa. ( Fuste, J; Gómez, M; Lorente, J; Risco, J; Rivas, MP; Sabater, F, 2014) |
| "This case report describes a paediatric patient diagnosed with otitis externa and treated with topical ciprofloxacin/dexamethasone." | 3.96 | Ciprofloxacin/dexamethasone precipitate formation in the ear canal of a paediatric patient. ( Curtis, SD; Ebied, AM; Egelund, EF, 2020) |
| "In the light of current concerns regarding ciprofloxacin resistance and the changing face of malignant otitis externa, we reviewed cases of malignant otitis externa treated in our centre, in order both to evaluate the current epidemiology of the condition and to assess the status of drug resistance in our patient population." | 3.76 | Malignant otitis externa: case series. ( Ali, T; Anari, S; ElBadawey, MR; Meade, K; Zammit-Maempel, I, 2010) |
| "Enoxacin was effective in 35%; ciprofloxacin (five publications) was used in 82 patients with 67% effectivity in otitis externa and otitis media and 61% effectivity in radical mastoid cavity infection." | 3.76 | The use of fluoroquinolones in chronic otitis suppurativa. ( Claes, J; Pattyn, SR; Valcke, HD; van Caekenberghe, DL; van de Heyning, PH, 1987) |
| "To compare treatment failure rates for the two major acute otitis externa (AOE) pathogens, Pseudomonas aeruginosa and Staphylococcus aureus, by topical therapy with ciprofloxacin 0." | 3.75 | Differences in bacteriologic treatment failures in acute otitis externa between ciprofloxacin/dexamethasone and neomycin/polymyxin B/hydrocortisone: results of a combined analysis. ( Dohar, JE; McLean, C; Roland, P; Stroman, DW; Wall, GM, 2009) |
| "For fifteen years oral ciprofloxacin has been the standard treatment for malignant otitis externa, a sometimes fatal osteomyelitis of the skull base usually caused by Pseudomonas aeruginosa." | 3.74 | Resistance of Pseudomonas to ciprofloxacin: implications for the treatment of malignant otitis externa. ( Bernstein, JM; Holland, NJ; Maw, AR; Porter, GC, 2007) |
| "A suspension formulation containing sarafloxacin HCl, triamcinolone acetonide, and clotrimazole was developed for the treatment of otitis externa in dogs." | 3.72 | Heat-induced formulation inhomogeneity of a three-component suspension. ( Chang, HC; Li, LC; Robinson, D; Stephens, D; Toongsuwan, S, 2004) |
| "In our series, resistance to ciprofloxacin in patients with malignant otitis externa is increasing over time." | 3.71 | Evolving resistant pseudomonas to ciprofloxacin in malignant otitis externa. ( Berenholz, L; Harell, M; Katzenell, U, 2002) |
| "At the Eastern Section Meeting of the Triological Society January 26, 1990, Levinson et al reported outstanding success with ciprofloxacin in the treatment of malignant otitis externa." | 3.68 | The fluoroquinolones. ( Brody, T; Pensak, ML, 1991) |
| "The efficacy and safety of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections was evaluated in 72 patients suffering from upper urinary tract infection (19 patients), deep soft tissue infection (16), chronic osteomyelitis (12), abscess (7), chronic otitis media (6), otitis externa (3) and bronchopneumonia (9)." | 3.67 | Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections. ( Daikos, GK; Daphnis, E; Dendrinos, C; Galanakis, N; Giamarellou, H; Stefanou, J, 1986) |
| " Fifteen adverse events related to study medications were registered, all of which were mild or moderate." | 3.11 | Efficacy and Safety of Ciprofloxacin Plus Fluocinolone Acetonide Among Patients With Acute Otitis Externa: A Randomized Clinical Trial. ( Aazami, H; Acosta, AM; Ansley, JF; Chu, L; De Valle, O; Dennis, P; Ehmer, D; Hedrick, JA, 2022) |
| "Foam-based ciprofloxacin is a safe and an effective new treatment for AOE." | 2.75 | Comparison of safety and efficacy of foam-based versus solution-based ciprofloxacin for acute otitis externa. ( Eilat, E; Goldfarb, A; Marom, T; Rakover, Y; Roth, Y; Shlizerman, L; Yelin, R, 2010) |
| " Repeated measures models were applied to log-transformed data to assess dosing trends and Pearson correlations were calculated to assess concentration associations." | 2.74 | Plasma and ear tissue concentrations of enrofloxacin and its metabolite ciprofloxacin in dogs with chronic end-stage otitis externa after intravenous administration of enrofloxacin. ( Cole, LK; Hillier, A; Kwochka, KW; Lehman, AM; Papich, MG; Smeak, DD, 2009) |
| " Most adverse events were mild and unrelated to study medication in both treatment groups." | 2.73 | Comparison of efficacy and safety of ciprofloxacin otic solution 0.2% versus polymyxin B-neomycin-hydrocortisone in the treatment of acute diffuse otitis externa*. ( Drehobl, M; Goldstein, G; Guerrero, JL; Lacarte, PR; Luber, S; Mata, FS, 2008) |
| "Signs and symptoms of AOE, including ear inflammation, tenderness, edema and discharge (assessed on Days 3, 8 [End-of-Therapy] and 18 [Test-of-Cure]); microbiologic eradication (presumed or documented); and frequency of adverse events." | 2.71 | Efficacy and safety of topical ciprofloxacin/dexamethasone versus neomycin/polymyxin B/hydrocortisone for otitis externa. ( Conroy, PJ; Dupre, SJ; Garadi, R; Henry, DC; Hogg, LG; Pien, FD; Potts, SL; Roland, PS; Schultz, CC; Stroman, DW; Wall, GM, 2004) |
| "Ciprofloxacin thus appears to be a useful and effective agent in the local therapy of otitis externa." | 2.67 | Otitis externa: clinical comparison of local ciprofloxacin versus local oxytetracycline, polymyxin B, hydrocortisone combination treatment. ( Arnes, E; Dibb, WL, 1993) |
| "Necrotising otitis externa is a progressive infection of the external auditory canal which extends to affect the temporal bone and adjacent structures." | 2.66 | A retrospective review and multi-specialty, evidence-based guideline for the management of necrotising otitis externa. ( Baring, D; Bennett, A; Henderson, N; Hopkins, ME; MacSween, KF; Sutherland, R, 2020) |
| "Ciprofloxacin has been shown to be effective against a wide range of gram-negative and gram-positive organisms." | 2.66 | Ciprofloxacin for the treatment of chronic ear disease. ( Parnes, SM; Piccirillo, JF, 1989) |
| "Ciprofloxacin/dexamethasone has been demonstrated as safe and effective with regard to clinical cures and microbiological eradication of pathogens in either disease with low treatment failure rates." | 2.45 | Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension for the topical treatment of ear infections: a review of the literature. ( Dohar, J; Roland, PS; Stroman, DW; Wall, GM, 2009) |
| " Due to the different dosing regimens, patients were not blinded, but they also were not directly informed of their treatment assignments." | 2.44 | Pooled analysis of two clinical trials comparing the clinical outcomes of topical ciprofloxacin/dexamethasone otic suspension and polymyxin B/neomycin/hydrocortisone otic suspension for the treatment of acute otitis externa in adults and children. ( Rahman, A; Rizwan, S; Wall, GM; Waycaster, C, 2007) |
| "Ciprofloxacin is the treatment of choice; however, it has to be in accordance to culture and sensitivity results." | 2.40 | Otitis externa malignant. A case report and review of literature. ( al Ammar, A; al Dousary, S; al Rabah, A; Attallh, M; Gaafar, M, 1998) |
| "Malignant external otitis is a serious infection most frequently caused by Pseudomonas aeruginosa." | 2.39 | Ciprofloxacin in the treatment of malignant external otitis. ( Gehanno, P, 1994) |
| "Necrotizing otitis externa is an invasive infection, affecting older patients, with significant associated morbidity." | 1.91 | Management and Clinical Outcomes of 37 Patients with Necrotizing Otitis Externa: Retrospective Review of a Standardized 6-Week Treatment Pathway. ( Beale, T; David, K; Dhariwal, A; Khetarpal, P; Logan, S; Manjaly, JG; Mehta, N; Morris-Jones, S; Patel, B, 2023) |
| "Tetracyclines are less toxic to cultured TM fibroblasts than ciprofloxacin." | 1.91 | Cytotoxicity of Tetracyclines in Human Tympanic Membrane Fibroblasts. ( Antonelli, PJ; Dirain, CO, 2023) |
| "Otitis externa is a common presentation to secondary care otolaryngology clinics." | 1.48 | Microbiology and antimicrobial susceptibility of otitis externa: a changing pattern of antimicrobial resistance. ( Cullen, M; Heward, E; Hobson, J, 2018) |
| "Otowicks are used to treat otitis externa with significant ear canal oedema." | 1.46 | Optimising the use of otowicks in otitis externa. ( Bola, S; Hickey, S; Rashid, M, 2017) |
| "Necrotizing otitis externa is an uncommon but potentially life-threatening infection disease of the external auditory canal and temporal bone." | 1.37 | Differential diagnosis and treatments of necrotizing otitis externa: a report of 19 cases. ( Chan, KC; Chen, CK; Chen, YA; Wu, CM, 2011) |
| "Osteomyelitis is an extremely unusual complication of invasive otitis externa." | 1.33 | [Temporomandibular osteomyelitis secondary to progressive necrotizing otitis externa]. ( Boulaïch, M; Filali, A; Jamal, H; Kzadri, M; Lazrak, A; Nazih, N; Oujilal, A, 2006) |
| "Orbifloxacin was tested at different concentrations for killing rate against five isolates obtained from pyoderma cases and against a reference strain (Staphylococcus aureus ATCC 29213)." | 1.32 | In vitro antimicrobial activity of orbifloxacin against Staphylococcus intermedius isolates from canine skin and ear infections. ( Etoré, F; Ganière, JP; Médaille, C, 2004) |
| "A patient with chronic lymphocytic leukemia developed a cutaneous infection with the clinical pattern of necrotizing otitis externa." | 1.32 | [Necrotizing otitis externa caused by Stenotrophomonas maltophilia]. ( Börner, D; Fischer, M; Marsch, WC, 2003) |
| "No cases of MOE in selective IgA deficiency have been reported in literature." | 1.31 | Malignant otitis externa in an infant with selective IgA deficiency: a case report. ( Balraj, A; Job, A; Justus, A; Kirubakaran, CP; Paul, AC, 2001) |
| "Ciprofloxacin resistance has increased, while Ceftazidime susceptibility is unchanged (> 90 %)." | 1.31 | [Current therapeutical management, new antibiotics and treatment of Pseudomonas aeruginosa in bacterial ENT-infections]. ( Elies, W, 2002) |
| "A patient with AIDS who had malignant otitis externa with skull base osteomyelitis is presented and reported cases in patients with AIDS are reviewed." | 1.29 | Malignant otitis externa in AIDS patients: case report and review of the literature. ( Schessel, D; Tuazon, CU; Weinroth, SE, 1994) |
| "Oral ciprofloxacin is an effective, convenient, nontoxic, economically justified alternative to the combination intravenous therapy previously advocated." | 1.28 | Successful treatment of malignant external otitis with oral ciprofloxacin: report of experience with 23 patients. ( Goshen, S; Kitzes-Cohen, R; Lang, R; Sadé, J, 1990) |
| "Malignant external otitis is an invasive pseudomonal infection characteristically afflicting the elderly patient with diabetes mellitus." | 1.28 | Efficacy of oral ciprofloxacin plus rifampin for treatment of malignant external otitis. ( Kamerer, DB; Matador, A; Muder, RR; Rubin, J; Stoehr, G; Yu, VL, 1989) |
| "The treatment with ciprofloxacin was well tolerated with no significant side effects, whereas serious side effects were noted in 45." | 1.28 | Ciprofloxacin treatment of malignant external otitis. ( Goshen, S; Kitzes-Cohen, R; Lang, R; Sadé, J, 1989) |
| "Ciprofloxacin is a quinolone with antipseudomonal activity which can be taken orally, and it is a useful alternative to the current treatment." | 1.27 | Necrotizing external otitis treated with ciprofloxacin. A case report. ( Carulla, M; Doménech, J; Loncá, M; Mensa, J; Sabater, F, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (16.47) | 18.7374 |
| 1990's | 18 (21.18) | 18.2507 |
| 2000's | 21 (24.71) | 29.6817 |
| 2010's | 21 (24.71) | 24.3611 |
| 2020's | 11 (12.94) | 2.80 |
| Authors | Studies |
|---|---|
| Mohammed, H | 1 |
| Mather, MW | 1 |
| Lumb, J | 1 |
| Butler, CC | 1 |
| Wilson, JA | 1 |
| Chu, L | 1 |
| Acosta, AM | 1 |
| Aazami, H | 1 |
| Dennis, P | 1 |
| De Valle, O | 1 |
| Ehmer, D | 1 |
| Hedrick, JA | 1 |
| Ansley, JF | 1 |
| Dirain, CO | 2 |
| Antonelli, PJ | 2 |
| Dhariwal, A | 1 |
| Manjaly, JG | 1 |
| Patel, B | 1 |
| Morris-Jones, S | 1 |
| David, K | 1 |
| Khetarpal, P | 1 |
| Beale, T | 1 |
| Mehta, N | 1 |
| Logan, S | 1 |
| Ahmed, MN | 1 |
| Shetty, P | 1 |
| Saunders, N | 1 |
| Bhutta, MF | 1 |
| Hopkins, ME | 1 |
| Bennett, A | 1 |
| Henderson, N | 1 |
| MacSween, KF | 1 |
| Baring, D | 1 |
| Sutherland, R | 1 |
| Byun, YJ | 1 |
| Patel, J | 1 |
| Nguyen, SA | 1 |
| Lambert, PR | 1 |
| Curtis, SD | 1 |
| Egelund, EF | 1 |
| Ebied, AM | 1 |
| Di Lullo, AM | 1 |
| Russo, C | 1 |
| Piroli, P | 1 |
| Petti, A | 1 |
| Capriglione, P | 1 |
| Cantone, E | 1 |
| Motta, G | 1 |
| Iengo, M | 1 |
| Elefante, A | 1 |
| Cavaliere, M | 1 |
| Frost, J | 1 |
| Samson, AD | 1 |
| Orhan Kubat, G | 1 |
| Dogan, B | 1 |
| Bola, S | 1 |
| Rashid, M | 1 |
| Hickey, S | 1 |
| Heward, E | 1 |
| Cullen, M | 1 |
| Hobson, J | 1 |
| Eguchi, T | 1 |
| Basugi, A | 1 |
| Kanai, I | 1 |
| Miyata, Y | 1 |
| Nasuno, T | 1 |
| Hamada, Y | 1 |
| Álvarez Millán, C | 1 |
| Bullido Gómez de Las Heras, E | 1 |
| Ansley, J | 1 |
| Mair, EA | 1 |
| Namini, H | 1 |
| Lu, CH | 1 |
| LeBel, C | 1 |
| Honnurappa, V | 1 |
| Ramdass, S | 1 |
| Mahajan, N | 1 |
| Vijayendra, VK | 1 |
| Redleaf, M | 1 |
| Lorente, J | 1 |
| Sabater, F | 2 |
| Rivas, MP | 1 |
| Fuste, J | 1 |
| Risco, J | 1 |
| Gómez, M | 1 |
| Crowson, MG | 1 |
| Schulz, K | 1 |
| Tucci, DL | 1 |
| Bhasker, D | 1 |
| Hartley, A | 1 |
| Agada, F | 1 |
| Drehobl, M | 1 |
| Guerrero, JL | 1 |
| Lacarte, PR | 1 |
| Goldstein, G | 1 |
| Mata, FS | 1 |
| Luber, S | 1 |
| Wall, GM | 4 |
| Stroman, DW | 3 |
| Roland, PS | 3 |
| Dohar, J | 1 |
| Cole, LK | 2 |
| Papich, MG | 1 |
| Kwochka, KW | 2 |
| Hillier, A | 2 |
| Smeak, DD | 2 |
| Lehman, AM | 1 |
| Dohar, JE | 1 |
| Roland, P | 1 |
| McLean, C | 1 |
| Ali, T | 1 |
| Meade, K | 1 |
| Anari, S | 1 |
| ElBadawey, MR | 1 |
| Zammit-Maempel, I | 1 |
| Lynsky, ML | 1 |
| Marom, T | 1 |
| Yelin, R | 1 |
| Goldfarb, A | 1 |
| Rakover, Y | 1 |
| Shlizerman, L | 1 |
| Eilat, E | 1 |
| Roth, Y | 1 |
| Fusconi, M | 1 |
| Chiarini, F | 1 |
| Taddei, AR | 1 |
| De Virgilio, A | 1 |
| Gallinelli, C | 1 |
| Conte, M | 1 |
| De Vincentiis, M | 1 |
| Nguyen, LT | 1 |
| Harris, JP | 1 |
| Nguyen, QT | 1 |
| Chen, YA | 1 |
| Chan, KC | 1 |
| Chen, CK | 1 |
| Wu, CM | 1 |
| Bock, K | 1 |
| Ovesen, T | 1 |
| Pulcini, C | 2 |
| Mahdyoun, P | 2 |
| Cua, E | 1 |
| Gahide, I | 2 |
| Castillo, L | 2 |
| Guevara, N | 2 |
| Panahi, Y | 1 |
| Akhavan, A | 1 |
| Sahebkar, A | 1 |
| Hosseini, SM | 1 |
| Taghizadeh, M | 1 |
| Akbari, H | 1 |
| Sharif, MR | 1 |
| Imani, S | 1 |
| Raffaelli, C | 1 |
| Berenholz, L | 1 |
| Katzenell, U | 1 |
| Harell, M | 1 |
| Isaacson, G | 1 |
| Börner, D | 1 |
| Marsch, WC | 1 |
| Fischer, M | 1 |
| Ganière, JP | 1 |
| Médaille, C | 1 |
| Etoré, F | 1 |
| Pien, FD | 1 |
| Schultz, CC | 1 |
| Henry, DC | 1 |
| Conroy, PJ | 1 |
| Garadi, R | 1 |
| Dupre, SJ | 1 |
| Potts, SL | 1 |
| Hogg, LG | 1 |
| Toongsuwan, S | 1 |
| Li, LC | 1 |
| Chang, HC | 1 |
| Stephens, D | 1 |
| Robinson, D | 1 |
| Kowalski, JJ | 1 |
| Kelbick, NT | 1 |
| Nazih, N | 1 |
| Filali, A | 1 |
| Boulaïch, M | 1 |
| Jamal, H | 1 |
| Oujilal, A | 1 |
| Lazrak, A | 1 |
| Kzadri, M | 1 |
| Bernstein, JM | 1 |
| Holland, NJ | 1 |
| Porter, GC | 1 |
| Maw, AR | 1 |
| Pino Rivero, V | 1 |
| Pantoja Hernández, CG | 1 |
| González Palomino, G | 1 |
| Mora Santos, ME | 1 |
| Pardo Romero, G | 1 |
| Blasco Huelva, A | 1 |
| Rahman, A | 1 |
| Rizwan, S | 1 |
| Waycaster, C | 1 |
| Joshua, BZ | 1 |
| Sulkes, J | 1 |
| Raveh, E | 1 |
| Bishara, J | 1 |
| Nageris, BI | 1 |
| Gehanno, P | 1 |
| Weinroth, SE | 1 |
| Schessel, D | 1 |
| Tuazon, CU | 1 |
| De Schepper, S | 1 |
| Schmelzer, B | 1 |
| Arnes, E | 1 |
| Dibb, WL | 1 |
| Cooper, MA | 1 |
| Andrews, JM | 1 |
| Wise, R | 1 |
| Ganz, H | 2 |
| Paramsothy, M | 1 |
| Khanijow, V | 1 |
| Ong, TO | 1 |
| al Dousary, S | 1 |
| Attallh, M | 1 |
| al Rabah, A | 1 |
| al Ammar, A | 1 |
| Gaafar, M | 1 |
| Wright, CG | 1 |
| Pawlowski, KS | 1 |
| Meyerhoff, WL | 1 |
| Kuczkowski, J | 1 |
| Samet, A | 1 |
| Brzoznowski, W | 1 |
| Paul, AC | 1 |
| Justus, A | 1 |
| Balraj, A | 1 |
| Job, A | 1 |
| Kirubakaran, CP | 1 |
| Elies, W | 1 |
| Gallen, IW | 1 |
| Molitch, ME | 1 |
| Garcia Rodriguez, JA | 1 |
| Montes Martinez, I | 1 |
| Gómez González, JL | 1 |
| Ramos Macías, A | 1 |
| López Alburquerque, T | 1 |
| Brody, T | 1 |
| Pensak, ML | 1 |
| Kindelan, JM | 1 |
| Jurado, R | 1 |
| No-Louis, E | 1 |
| López-Villarejo, P | 1 |
| Levenson, MJ | 1 |
| Parisier, SC | 1 |
| Dolitsky, J | 1 |
| Bindra, G | 1 |
| Strauss, M | 1 |
| Rivas Lacarte, MP | 1 |
| Pumarola Segura, F | 1 |
| Lang, R | 2 |
| Goshen, S | 2 |
| Kitzes-Cohen, R | 2 |
| Sadé, J | 2 |
| Hickey, SA | 2 |
| Eykyn, SJ | 2 |
| Pickard, RE | 1 |
| Rubin, J | 1 |
| Stoehr, G | 1 |
| Yu, VL | 1 |
| Muder, RR | 1 |
| Matador, A | 1 |
| Kamerer, DB | 1 |
| Ford, GR | 1 |
| O'Connor, AF | 1 |
| Sönksen, PH | 1 |
| Fairley, J | 1 |
| Glover, GW | 1 |
| Stange, G | 1 |
| Piccirillo, JF | 1 |
| Parnes, SM | 1 |
| Noel, SB | 1 |
| Scallan, P | 1 |
| Meadors, MC | 1 |
| Meek, TJ | 1 |
| Pankey, GA | 1 |
| Osborne, JE | 1 |
| Blair, RL | 1 |
| Davey, P | 1 |
| Giamarellou, H | 1 |
| Galanakis, N | 1 |
| Dendrinos, C | 1 |
| Stefanou, J | 1 |
| Daphnis, E | 1 |
| Daikos, GK | 1 |
| Morrison, GA | 1 |
| Bailey, CM | 1 |
| van de Heyning, PH | 1 |
| Pattyn, SR | 1 |
| Valcke, HD | 1 |
| van Caekenberghe, DL | 1 |
| Claes, J | 1 |
| Leggett, JM | 1 |
| Prendergast, K | 1 |
| Mensa, J | 1 |
| Doménech, J | 1 |
| Loncá, M | 1 |
| Carulla, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Assess the Efficacy and Safety of DF289 Plus DF277 Otic Solution Compared to DF289 Otic Solution and to DF277 Otic Solution in the Treatment of Acute Otitis Externa (AOE)[NCT03196973] | Phase 3 | 493 participants (Actual) | Interventional | 2017-07-22 | Completed | ||
| N-Acetylcysteine as an Adjunct for Refractory Chronic Suppurative Otitis Media[NCT00956748] | Phase 4 | 0 participants (Actual) | Interventional | 2019-11-29 | Withdrawn (stopped due to Lack of staff, time, and resources) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Therapeutic cure will be considered achieved if edema, otalgia and otorrhea are resolved with no further requirement of antimicrobial therapy and bacteriological response is Eradication or Presumed Eradication (NCT03196973)
Timeframe: End of Treatment (Day 8+2)
| Intervention | Participants (Count of Participants) |
|---|---|
| DF289 Plus DF277 | 63 |
| DF289 | 49 |
| DF277 | 20 |
First day on which there is no use of analgesics, the pain score is zero and remains zero until end of study (NCT03196973)
Timeframe: From baseline to End of Study (Day 15+2)
| Intervention | days (Median) |
|---|---|
| DF289 Plus DF277 | 5.0 |
| DF289 | 5.9 |
| DF277 | 7.7 |
9 reviews available for ciprofloxacin and Otitis Externa
| Article | Year |
|---|---|
A retrospective review and multi-specialty, evidence-based guideline for the management of necrotising otitis externa.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Cranial Nerve Diseases; Disease Progr | 2020 |
Necrotizing Otitis Externa: A Systematic Review and Analysis of Changing Trends.
Topics: Aged; Ciprofloxacin; Humans; Otitis Externa; Prevalence | 2020 |
Malignant Otitis External: Our Experience and Literature Review.
Topics: Aged; Ciprofloxacin; Diabetes Mellitus, Type 2; Humans; Magnetic Resonance Imaging; Male; Otitis Ext | 2020 |
Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension for the topical treatment of ear infections: a review of the literature.
Topics: Administration, Topical; Anti-Infective Agents; Anti-Inflammatory Agents; Ciprofloxacin; Dexamethaso | 2009 |
Antibiotic therapy in necrotising external otitis: case series of 32 patients and review of the literature.
Topics: Adult; Aged; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Drug Therapy, Combination; Female; F | 2012 |
Pooled analysis of two clinical trials comparing the clinical outcomes of topical ciprofloxacin/dexamethasone otic suspension and polymyxin B/neomycin/hydrocortisone otic suspension for the treatment of acute otitis externa in adults and children.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inf | 2007 |
Ciprofloxacin in the treatment of malignant external otitis.
Topics: Administration, Oral; Aged; Ciprofloxacin; Drug Administration Schedule; Enterobacteriaceae; Female; | 1994 |
Otitis externa malignant. A case report and review of literature.
Topics: Anti-Infective Agents; Ciprofloxacin; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Otitis | 1998 |
The use of fluoroquinolones in chronic otitis suppurativa.
Topics: Cholesteatoma; Chronic Disease; Ciprofloxacin; Clinical Trials as Topic; Enoxacin; Humans; Mastoidit | 1987 |
12 trials available for ciprofloxacin and Otitis Externa
| Article | Year |
|---|---|
Efficacy and Safety of Ciprofloxacin Plus Fluocinolone Acetonide Among Patients With Acute Otitis Externa: A Randomized Clinical Trial.
Topics: Acute Disease; Administration, Topical; Adult; Anti-Bacterial Agents; Ciprofloxacin; Earache; Female | 2022 |
OTO-201 for the Treatment of Acute Otitis Externa: Results from a Phase 3 Randomized Clinical Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Child, Preschool; Ciproflo | 2019 |
Ciprofloxacin plus fluocinolone acetonide versus ciprofloxacin alone in the treatment of diffuse otitis externa.
Topics: Administration, Topical; Adolescent; Adult; Anti-Bacterial Agents; Child; Ciprofloxacin; Dose-Respon | 2014 |
Comparison of efficacy and safety of ciprofloxacin otic solution 0.2% versus polymyxin B-neomycin-hydrocortisone in the treatment of acute diffuse otitis externa*.
Topics: Acute Disease; Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial A | 2008 |
Plasma and ear tissue concentrations of enrofloxacin and its metabolite ciprofloxacin in dogs with chronic end-stage otitis externa after intravenous administration of enrofloxacin.
Topics: Animals; Anti-Bacterial Agents; Chronic Disease; Ciprofloxacin; Dog Diseases; Dogs; Dose-Response Re | 2009 |
Comparison of safety and efficacy of foam-based versus solution-based ciprofloxacin for acute otitis externa.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Ciprofloxacin; Dosage Forms; F | 2010 |
Investigation of the effectiveness of Syzygium aromaticum, Lavandula angustifolia and Geranium robertianum essential oils in the treatment of acute external otitis: a comparative trial with ciprofloxacin.
Topics: Adult; Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Female; Humans; Magnoliopsida; Male; Middle A | 2014 |
Efficacy and safety of topical ciprofloxacin/dexamethasone versus neomycin/polymyxin B/hydrocortisone for otitis externa.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; C | 2004 |
Ciprofloxacin as a representative of disk diffusion in vitro susceptibility of enrofloxacin for bacterial organisms from the middle-ear tissue of dogs with end-stage otitis externa.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Dog Diseases; Dogs; Enrofloxacin; Female; Fluoroquino | 2006 |
Otitis externa: clinical comparison of local ciprofloxacin versus local oxytetracycline, polymyxin B, hydrocortisone combination treatment.
Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents; Ciprofloxacin; Drug Combinations; Dr | 1993 |
Ciprofloxacin for the treatment of chronic ear disease.
Topics: Adult; Aged; Cholesteatoma; Chronic Disease; Ciprofloxacin; Clinical Trials as Topic; Female; Humans | 1989 |
The use of fluoroquinolones in chronic otitis suppurativa.
Topics: Cholesteatoma; Chronic Disease; Ciprofloxacin; Clinical Trials as Topic; Enoxacin; Humans; Mastoidit | 1987 |
65 other studies available for ciprofloxacin and Otitis Externa
| Article | Year |
|---|---|
Otitis externa: what is the problem with getting it right? A mixed-methods study in primary and secondary care.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Humans; Otitis Externa; Secondary Care; State Medicine | 2022 |
Cytotoxicity of Tetracyclines in Human Tympanic Membrane Fibroblasts.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Doxycycline; Fibroblasts; Humans; Minocycline; Otitis | 2023 |
Management and Clinical Outcomes of 37 Patients with Necrotizing Otitis Externa: Retrospective Review of a Standardized 6-Week Treatment Pathway.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Humans; Otitis Externa; Pseudo | 2023 |
Permanent Facial Paralysis and Hearing Loss After Aural Irrigation.
Topics: Aged; Anti-Bacterial Agents; Cerumen; Ciprofloxacin; Facial Paralysis; Female; Hearing Loss, Mixed C | 2020 |
Ciprofloxacin/dexamethasone precipitate formation in the ear canal of a paediatric patient.
Topics: Administration, Topical; Adolescent; Anti-Bacterial Agents; Anti-Inflammatory Agents; Ciprofloxacin; | 2020 |
Standardised treatment protocol for necrotizing otitis externa: retrospective case series and systematic literature review.
Topics: Aged, 80 and over; Ciprofloxacin; Clinical Protocols; Humans; Otitis Externa; Pseudomonas aeruginosa | 2021 |
Identification of pathogens isolated in acute external otitis cases and evaluation of aminoglycoside and quinolone sensitivity.
Topics: Acute Disease; Administration, Topical; Adult; Age Factors; Amikacin; Aminoglycosides; Anti-Bacteria | 2021 |
Optimising the use of otowicks in otitis externa.
Topics: Ciprofloxacin; Drug Carriers; Gentamicins; Humans; Instillation, Drug; Otitis Externa; Tampons, Surg | 2017 |
Microbiology and antimicrobial susceptibility of otitis externa: a changing pattern of antimicrobial resistance.
Topics: Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Candida; Candidiasis; Ciprofloxacin | 2018 |
Malignant external otitis following radiotherapy for oral cancer: A case report.
Topics: Administration, Intravenous; Aged; Anti-Bacterial Agents; Asian People; Carcinoma, Squamous Cell; Ci | 2018 |
Ciprofloxacin otic suspension (Otiprio) for acute otitis externa.
Topics: Acute Disease; Administration, Topical; Anti-Bacterial Agents; Ciprofloxacin; Drug Approval; Humans; | 2018 |
Ciprofloxacin Otic Suspension and Permanent Peripheral Neuropathy.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Otitis Externa; Peripheral Nervous System Diseases; R | 2019 |
Response to the Letter to the Editor: "Ciprofloxacin Otic Suspension and Permanent Peripheral Neuropathy".
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Otitis Externa; Peripheral Nervous System Diseases; R | 2019 |
Effective Inexpensive Management of Necrotizing Otitis Externa Is Possible in Resource-Poor Settings.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Earache; Female; Humans; India; Male; Meropenem; Middle Aged; | 2019 |
National Utilization and Forecasting of Ototopical Antibiotics: Medicaid Data Versus "Dr. Google".
Topics: Anti-Bacterial Agents; Ciprofloxacin; Databases, Factual; Dexamethasone; Drug Combinations; Forecast | 2016 |
Is malignant otitis externa on the increase? A retrospective review of cases.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Female; Humans; Male; Middle A | 2017 |
Differences in bacteriologic treatment failures in acute otitis externa between ciprofloxacin/dexamethasone and neomycin/polymyxin B/hydrocortisone: results of a combined analysis.
Topics: Acute Disease; Administration, Topical; Ciprofloxacin; Dexamethasone; Drug Therapy, Combination; Hum | 2009 |
Malignant otitis externa: case series.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Cranial Nerve Diseases; Diabetes Mell | 2010 |
A 14-year-old boy with left ear pain.
Topics: Administration, Oral; Administration, Topical; Adolescent; Amoxicillin; Anti-Bacterial Agents; Cipro | 2010 |
Chemical ear peeling: a simple technique for the treatment of chronic external otitis: how we do it.
Topics: Acetic Acid; Bacterial Infections; Chemexfoliation; Chronic Disease; Ciprofloxacin; Cortisone; Drug | 2010 |
Erosive external otitis: a novel distinct clinical entity of the external auditory canal in nonimmunosuppressed individuals.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Debridement; Down Syndrome; Ear Canal; Eust | 2010 |
Differential diagnosis and treatments of necrotizing otitis externa: a report of 19 cases.
Topics: Adult; Aged; Aged, 80 and over; Ciprofloxacin; Comorbidity; Diabetes Complications; Diagnosis, Diffe | 2011 |
Optimised diagnosis and treatment of necrotizing external otitis is warranted.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; C-Reactive Protein; Ci | 2011 |
Initial management of necrotizing external otitis: errors to avoid.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents, Local; Ceftazidime; Ci | 2013 |
Evolving resistant pseudomonas to ciprofloxacin in malignant otitis externa.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Female; H | 2002 |
Treatment of otitis externa.
Topics: Amoxicillin; Candida; Child, Preschool; Ciprofloxacin; Female; Gram-Negative Bacteria; Gram-Positive | 2003 |
[Necrotizing otitis externa caused by Stenotrophomonas maltophilia].
Topics: Anti-Infective Agents; Bacteriological Techniques; Biopsy; Ciprofloxacin; Cross Infection; Dose-Resp | 2003 |
In vitro antimicrobial activity of orbifloxacin against Staphylococcus intermedius isolates from canine skin and ear infections.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Dog Diseases; Dogs; Drug Resistance, Bacterial; Micro | 2004 |
Heat-induced formulation inhomogeneity of a three-component suspension.
Topics: Animals; Anti-Infective Agents, Local; Chemistry, Pharmaceutical; Chromatography, High Pressure Liqu | 2004 |
[Temporomandibular osteomyelitis secondary to progressive necrotizing otitis externa].
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Gentamicins; Humans; Male; Necrosis; Osteomyelitis; Otit | 2006 |
[Otitis externa: which antibiotics are first choice?].
Topics: Anti-Bacterial Agents; Cephalosporins; Ciprofloxacin; Clindamycin; Drug Therapy, Combination; Humans | 2006 |
Resistance of Pseudomonas to ciprofloxacin: implications for the treatment of malignant otitis externa.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Bacterial; Female; H | 2007 |
[Pseudomonas and acute external otitis. Results of a microbiological study in patients without previous antibiotic treatment].
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Age Factors; Aged; Anti-Bacterial Agents; An | 2007 |
Predicting outcome of malignant external otitis.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; | 2008 |
Malignant otitis externa in AIDS patients: case report and review of the literature.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Bacterial Agents; Bone Diseases; Ciprofloxacin; Huma | 1994 |
[Local treatment of otitis media and otitis externa: the role of quinolones].
Topics: Audiometry; Ciprofloxacin; Female; Humans; Male; Otitis Externa; Otitis Media, Suppurative | 1994 |
Ciprofloxacin resistance developing during treatment of malignant otitis externa.
Topics: Adult; Ciprofloxacin; Drug Resistance, Microbial; Humans; Male; Otitis Externa | 1993 |
[Bacterial otitis externa with invasion of organ limits--systemic and local combination treatment with ciprofloxacin].
Topics: Administration, Topical; Bacterial Infections; Ciprofloxacin; Humans; Microbial Sensitivity Tests; O | 1993 |
Use of gallium-67 in the assessment of response to antibiotic therapy in malignant otitis externa--a case report.
Topics: Anti-Infective Agents; Ciprofloxacin; Gallium Radioisotopes; Humans; Male; Middle Aged; Otitis Exter | 1997 |
An animal model for external ear canal inflammation.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Ciprofloxacin; De | 2000 |
[Bacteriologic evaluation of otitis externa and chronic otitis media].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Aspergillus; Bacteria; Candida; Child; Chronic | 2000 |
Malignant otitis externa in an infant with selective IgA deficiency: a case report.
Topics: Child, Preschool; Ciprofloxacin; Cloxacillin; Combined Modality Therapy; Debridement; Drug Therapy, | 2001 |
[Current therapeutical management, new antibiotics and treatment of Pseudomonas aeruginosa in bacterial ENT-infections].
Topics: Ceftazidime; Chronic Disease; Ciprofloxacin; Clinical Trials as Topic; Dose-Response Relationship, D | 2002 |
Treatment of malignant otitis externa in a younger diabetes patient.
Topics: Adult; Ciprofloxacin; Diabetes Mellitus, Type 1; Female; Humans; Otitis Externa; Pseudomonas aerugin | 1992 |
A case of malignant external otitis involving Klebsiella oxytoca.
Topics: Aged; Aged, 80 and over; Ciprofloxacin; Drug Administration Schedule; Humans; Klebsiella; Klebsiella | 1992 |
The fluoroquinolones.
Topics: Bacterial Infections; Ciprofloxacin; Humans; Norfloxacin; Otitis Externa | 1991 |
[Otitis externa maligna. Report of a case resistant to ciprofloxacin].
Topics: Aged; Aged, 80 and over; Ceftazidime; Ciprofloxacin; Diabetes Mellitus, Type 1; Drug Resistance, Mic | 1991 |
Ciprofloxacin: drug of choice in the treatment of malignant external otitis (MEO).
Topics: Aged; Aged, 80 and over; Chronic Disease; Ciprofloxacin; Female; Follow-Up Studies; Humans; Male; Mi | 1991 |
Current therapy of malignant external otitis.
Topics: Aged; Cefoperazone; Ceftazidime; Ciprofloxacin; Diabetes Mellitus, Type 1; Drug Therapy, Combination | 1990 |
[Malignant otitis externa and HIV antibodies. A case report].
Topics: Acquired Immunodeficiency Syndrome; Adult; Ciprofloxacin; Drug Therapy, Combination; Gentamicins; HI | 1990 |
Successful treatment of malignant external otitis with oral ciprofloxacin: report of experience with 23 patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ciprofloxacin; Combined Modality Therapy; Debridement | 1990 |
Successful treatment of malignant otitis externa with oral ciprofloxacin.
Topics: Adult; Aged; Ciprofloxacin; Humans; Middle Aged; Otitis Externa; Remission Induction | 1990 |
Caution indicated in prescribing ciprofloxacin.
Topics: Ciprofloxacin; Humans; Otitis Externa; Pseudomonas Infections | 1990 |
Efficacy of oral ciprofloxacin plus rifampin for treatment of malignant external otitis.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Blood Sedimentation; Ciprofloxacin; Diabetes Complic | 1989 |
Treating malignant otitis with oral ciprofloxacin.
Topics: Administration, Oral; Aged; Ciprofloxacin; Ear, External; Humans; Male; Middle Aged; Otitis Externa; | 1989 |
Treating malignant otitis with oral ciprofloxacin.
Topics: Administration, Oral; Ciprofloxacin; Humans; Male; Middle Aged; Otitis Externa | 1989 |
[Local treatment of Pseudomonas infection of the ear. A small clinical study].
Topics: Audiometry, Pure-Tone; Auditory Threshold; Ciprofloxacin; Follow-Up Studies; Humans; Otitis Externa; | 1989 |
Ciprofloxacin treatment of malignant external otitis.
Topics: Aged; Aged, 80 and over; Ciprofloxacin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Otitis | 1989 |
Treatment of Pseudomonas aeruginosa auricular perichondritis with oral ciprofloxacin.
Topics: Administration, Oral; Aged; Ciprofloxacin; Female; Humans; Male; Middle Aged; Otitis Externa; Pseudo | 1989 |
Successful treatment of malignant otitis externa with oral ciprofloxacin.
Topics: Administration, Oral; Adult; Ciprofloxacin; Humans; Male; Otitis Externa; Pseudomonas Infections | 1989 |
[Local antibiotic therapy of bacterial ear infections].
Topics: Administration, Topical; Bacterial Infections; Ciprofloxacin; Humans; Lymphadenitis; Mastoiditis; Ot | 1989 |
Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.
Topics: Abscess; Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Bronchopneumonia; Chi | 1986 |
Relapsing malignant otitis externa successfully treated with ciprofloxacin.
Topics: Aged; Ciprofloxacin; Humans; Male; Otitis Externa; Pseudomonas Infections; Radionuclide Imaging; Rec | 1988 |
Malignant external otitis: the use of oral ciprofloxacin.
Topics: Administration, Oral; Aged; Ciprofloxacin; Female; Humans; Otitis Externa; Pseudomonas Infections | 1988 |
Necrotizing external otitis treated with ciprofloxacin. A case report.
Topics: Aged; Ciprofloxacin; Humans; Male; Necrosis; Otitis Externa; Tomography, X-Ray Computed | 1988 |